FINAL EXAM JUNE 2012

NATIONAL BOARD OF EXAMINATIONS

CARDIOLOGY

PAPER-I

Time: 3 hours Max. Marks : 100 CARD/J/12/05/I

Attempt all questions in order. Each question carries 10 marks.

1.	Describe coagulation pathways and indicate where the anticoagulants	5+5
	interfere.	
2.	Describe the anatomy of triangle of Koch's. Explain the mechanism of	3+4+3
	paroxysmal junctional reciprocating tachycardia. How is it treated?	
3.	What are hypercoagulable states? What are the laboratory tests for their	3+3+4
	diagnosis? Outline management of hypercoagulable state.	
4.	Describe invasive and non-invasive evaluation of pulmonary arterial	3+3+4
	hypertension. How will you assess reversibility?	
5.	What is coronary flow reserve? Describe its clinical significance.	5+5
6.	Discuss genetics & manifestation of ventricular non-compaction.	5+5
7.	Describe embryogenesis of conotruncal anomalies. Classify double	4+3+3
	outlet right ventricle and correlate with manifestations.	
8.	Describe Fick principle and estimation of cardiac output by this principle.	5+5
9.	Discuss the principles and cardiovascular applications of Optical	5+5
	Coherence Tomography (OCT).	
10.	Discuss genetics of long QT syndrome & its clinical relevance.	5+5

FINAL EXAM JUNE 2012

NATIONAL BOARD OF EXAMINATIONS

CARDIOLOGY

PAPER-II

Time: 3 hours Max. Marks : 100 CARD/J/12/05/II

Attempt all questions in order. Each question carries 10 marks.

1.	Outline the manifestation, evaluation, diagnosis and management of	2+3+3+2
	HFNEF (Heart Failure with Normal Ejection Fraction).	
2.	Describe etiopathogenesis and evaluation of left main coronary disease.	3+3+4
	What is the current status of its management?	
3.	Describe in brief the role of left atrial appendage in thromboembolism.	4+6
	Outline current status of left atrial appendage occluder devices.	
4.	Describe general principles, indications and regimens for infective	3+3+4
	endocarditis prophylaxis.	
5.	What are the causes and manifestation of loss of capture in cardiac	2+2+3+3
	pacing? Describe its diagnosis and management.	
6.	What is the etiopathogenesis, manifestation and management of ARVC	2+4+4
	(Arrhythmogenic Right Ventricular Cardiomyopathy)?	
7.	Describe anti-thrombotic therapy for non-cardiac surgery in post	10
	coronary stenting.	
8.	What is peripartum cardiomyopathy? Discuss its risk factors; treatment	3+3+3+1
	and prognosis.	
9.	Discuss etiology and management of pacemaker implant infection.	5+5
10.	What is stent thrombosis? Discuss its etiopathogenesis and diagnostic	2+4+4
	criteria.	

FINAL EXAM JUNE 2012

NATIONAL BOARD OF EXAMINATIONS

CARDIOLOGY

PAPER-III

Time: 3 hours Max. Marks : 100 CARD/J/12/05/III

Attempt all questions in order. Each question carries 10 marks.

1.	Describe 'COURAGE Trial'. What is the contribution of the trial to clinical	4+6
	practice?	
2.	Discuss the role of MRI in ischemic cardiomyopathy, hypertrophic	3+3+4
	cardiomyopathy & arrhythmogenic right ventricular dysplasia.	
3.	What are bioabsorbable stents? Outline their current status.	3+7
4.	What is micro T wave alterans? What is their role in cardiac	3+7
	arrhythmogenesis?	
5.	Discuss current status of fetal cardiac intervention.	10
6.	Discuss current status of PFO (patent foramen ovale) in cardiovascular	6+4
	disease and PFO closure.	
7.	Discuss indications and current status of tissue heart valves.	3+7
8.	What are drug eluting balloons? What is their present status in	5+5
	interventions?	
9.	What are leadless pacemakers? What is the current status of leadless	5+5
	permanent cardiac pacing devices?	
10.	Discuss the role of renal denervation in treatment of hypertension	10
